Overview

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Status:
Completed

Trial end date:
2021-09-24

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as confirm the recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent chemotherapy regimen, doxorubicin (Adriamycin), vinblastine, and dacarbazine, in pediatric participants with advanced stage newly diagnosed classical CD30+ Hodgkin Lymphoma (HL).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Millennium Pharmaceuticals, Inc.
Takeda

Treatments:

Antibodies, Monoclonal
Brentuximab Vedotin
Dacarbazine
Doxorubicin
Liposomal doxorubicin
Vinblastine